New Magnetic Resonance Imaging Biomarkers in Amyotrophic Lateral Sclerosis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

22 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-06-16

Study Completion Date

2025-06-04

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Amyotrophic lateral sclerosis (ALS) is a disabling and rapidly progressive neurodegenerative disorder. There is no treatment that significantly slows progression. Our project aims to find new biomarkers in MRI at three levels: cerebral, medullary and muscular. These markers could allow an earlier diagnosis of the disease by showing more specific lesions of ALS and to quantify these lesions to measure the progression of the disease. This study will use advanced Magnetic Resonance Imaging (MRI) techniques High field (3T) and very high field (7T) MRI. Results from neurological and electrophysiological tests will be compared to the MRI. Subjects will be recruited from ALS center of Marseille, France. MRI will be done on ALS patients at baseline, at 3 month and at 6 month intervals.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Imaging and BioFluid Biomarkers in Amyotrophic Lateral Sclerosis

NCT02559869

Amyotrophic Lateral Sclerosis (ALS)

COMPLETED

Study of miRNA Expression Pattern as Diagnostic and Prognostic Biomarker in Amyotrophic Lateral Sclerosis

NCT01992029

Amyotrophic Lateral Sclerosis ALS

TERMINATED

Cervical Spinal Cord Metabolism and Microstructure in Amyotrophic Lateral Sclerosis(ALS)

NCT02000713

Amyotrophic Lateral Sclerosis

TERMINATED NA

Noninvasive Assessment of Neuronal Damage by MRI Sodium ( 23Na ) in Amyotrophic Lateral Sclerosis

NCT02874209

Amyotrophic Lateral Sclerosis

UNKNOWN NA

Imaging Biomarkers in ALS

NCT02567136

Amyotrophic Lateral Sclerosis Primary Lateral Sclerosis

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Amyotrophic Lateral Sclerosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

3 groups :

* muscle
* brain
* spinal cord

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Muscle

Group Type OTHER

Muscular MRI

Intervention Type OTHER

MRI (1.5T)

Electrophysiological exam

Intervention Type OTHER

MUNIX

Spinal cord

Group Type OTHER

Muscular MRI

Intervention Type OTHER

MRI (1.5T)

Electrophysiological exam

Intervention Type OTHER

MUNIX

Spinal cord MRI

Intervention Type OTHER

7T and 3T MRI

Brain

Group Type OTHER

Muscular MRI

Intervention Type OTHER

MRI (1.5T)

Electrophysiological exam

Intervention Type OTHER

MUNIX

Brain MRI

Intervention Type OTHER

MRI (7T)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Muscular MRI

MRI (1.5T)

Intervention Type OTHER

Electrophysiological exam

MUNIX

Intervention Type OTHER

Brain MRI

MRI (7T)

Intervention Type OTHER

Spinal cord MRI

7T and 3T MRI

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients will be adults with a diagnosis of ALS.
* Healthy controls will also be recruited and will be age- and gender-matched to patients.
* Patients able to undergo a brain MRI for approximately an hour.

Exclusion Criteria

* Subjects with other psychiatric or CNS or PNS diseases.
* Subjects ineligible for MRI investigation due to a pacemaker or other metallic foreign body, or significant claustrophobia that could affect the ability to have an MRI scan.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes